Invesco
CGON icon

Invesco’s CG Oncology CGON Stock Holding History

Invesco’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.72M Sell
52,406
-39,588
-43% -$2.59M ﹤0.01% 2338
2026
Q1 		$6.23M Buy
91,994
+53,854
+141% +$3.05M ﹤0.01% 2090
2025
Q4 		$1.58M Buy
38,140
+3,761
+11% +$156K ﹤0.01% 2706
2025
Q3 		$1.38M Buy
34,379
+5,148
+18% +$150K ﹤0.01% 2781
2025
Q2 		$760K Buy
29,231
+1,477
+5% +$35.6K ﹤0.01% 2972
2025
Q1 		$680K Buy
27,754
+685
+3% +$19.3K ﹤0.01% 3026
2024
Q4 		$776K Buy
27,069
+11,662
+76% +$399K ﹤0.01% 3021
2024
Q3 		$581K Buy
15,407
+3,001
+24% +$105K ﹤0.01% 3168
2024
Q2 		$392K Buy
12,406
+223
+2% +$7.73K ﹤0.01% 3378
2024
Q1 		$535K Buy
+12,183
New +$498K ﹤0.01% 3297

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco's CGON Position: Q2 2026 in Review

Invesco reduced its CG Oncology (CGON) stake by 43% in Q2 2026, selling an estimated $2.59M and leaving 52,406 shares worth $3.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2338.

Invesco first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. The position peaked at $6.23M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Invesco held 52,406 shares of CG Oncology worth $3.72M as of Q2 2026.
  • Invesco sold 39,588 CG Oncology shares in Q2 2026, an estimated $2.59M.
  • CG Oncology made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2338 holding.
  • Invesco first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • Invesco's CG Oncology position peaked at $6.23M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.